Capricor Therapeutics is an American biotechnology company developing cell- and exosome-based therapies. Its main project, Deramiocel, is a treatment for Duchenne muscular dystrophy aimed at slowing muscle degeneration and improving heart function. The company currently has no approved products and relies on clinical trial outcomes and regulatory decisions.
Disclaimer
All content provided on this website (https://wildinwest.com/) -including attachments, links, or referenced materials — is for informative and entertainment purposes only and should not be considered as financial advice. Third-party materials remain the property of their respective owners.